Bladder Cancer

Why trials studying Bladder Cancer stopped, in this sample of ClinicalTrials.gov.

20 stopped trials with a clear reason; 80% ended for non-scientific reasons.

Trials

• A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial
  NCT06301308 · WITHDRAWN · slow accrual
  “The standard measures of anaesthesia in cystoscopy are not uniform internationally, and given this, we were unable to recruit the first participant in the study.”
• TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
  NCT05655598 · WITHDRAWN · slow accrual
  “Lack of accrual”
• A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer
  NCT05699135 · TERMINATED · funding business
  “The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns.”
• Assessement of the Concordance of Genomic Alterations Between Urine and Tissue in High-Risk NMIBC Patients
  NCT04412070 · TERMINATED · slow accrual
  “The target enrollment was not reached at the end of recrutement period. The presence of a concurrent therapeutic clinical trial in the same department significantly limited patient availability for this study, making further recruitment not feasible.”
• A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)
  NCT04089163 · WITHDRAWN · funding business
  “Sponsor decision.”
• Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
  NCT04234113 · TERMINATED · futility
  “Due to lack of efficacy shown at the time of the interim analysis.”
• A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors
  NCT03960060 · TERMINATED · funding business
  “Adjustment of study strategy”
• Novel mRNA-based Urine Test for Bladder Cancer in Spinal Cord Injury Individuals
  NCT02538809 · TERMINATED · slow accrual
  “insufficient recruitment”
• A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
  NCT02576665 · TERMINATED · funding business
  “Sponsor decision”
• Observation Versus Immediate Surgery of Low Risk Bladder Cancer
  NCT02700724 · TERMINATED · slow accrual
  “poor enrollment”
• LCI-GU-BLA-SPEC-001: Aurora Kinase Expression in Muscle-Invasive Bladder Cancer
  NCT02164942 · TERMINATED · futility
  “Futility”
• A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies
  NCT01060319 · WITHDRAWN · funding business
  “Business Decision”
• Intravesical BCG Administration to Patients With Invasive Bladder Cancer
  NCT02365207 · TERMINATED · slow accrual
  “Poor accrual of subjects and lack of funding”
• Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors
  NCT01496534 · TERMINATED · safety
  “toxicity of combination of medications”
• Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer
  NCT01410565 · TERMINATED · funding business
  “Business reason”
• Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
  NCT01331824 · TERMINATED · funding business
  “due to a development decision by the funder”
• A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)
  NCT01094496 · TERMINATED · slow accrual
  “Portfolio prioritization due to slow enrollment”
• Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer
  NCT00880854 · WITHDRAWN · slow accrual
  “Lack of accrual”
• S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer
  NCT00003824 · TERMINATED · slow accrual
  “Permanently Closed Due to Poor Accrual”
• 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
  NCT00005047 · TERMINATED · futility
  “Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility analysis.”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.